Cataract conversion assessment using lens opacity classification system III and Wisconsin cataract grading system

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 280-287

  Wong, Wan Ling ^a,b,c   Li, Xiang ^a,d   Li, Jialiang ^a,d   Cheng, Ching Yu ^a,c   Lamoureux, Ecosse L ^a,e   Wang, Jie Jin ^e,f   Cheung, Carol Y ^a,b   Wong, Tien Yin ^a,b,c,e  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; BIOMICROSCOPY; BLINDNESS; CATARACT; CLASSIFICATION; CLINICAL ASSESSMENT; CONTINGENCY TABLE; ETHNICITY; HUMAN; INTRARATER RELIABILITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SLIT LAMP; VALIDATION PROCESS; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CATARACT; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; HUMANS; LENS, CRYSTALLINE; MIDDLE AGED; PHOTOGRAPHY;

EID: 84874669710     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10657     Document Type: Article

References (53)

1. Thylefors B. The World Health Organization's programme for the prevention of blindness. Int Ophthalmol. 1990;14:211-219.
2. Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ. 1995;73:115-121.
3. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11:67-115.
4. Congdon N, West SK, Buhrmann RR, et al. Prevalence of the different types of age-related cataract in an African population. Invest Ophthalmol Vis Sci. 2001;42:2478-2482.
5. Deane JS, Hall AB, Thompson JR, Rosenthal AR. Prevalence of lenticular abnormalities in a population-based study: Oxford Clinical Cataract Grading in the Melton Eye Study. Ophthalmic Epidemiol. 1997;4:195-206.
6. Giuffre G, Giammanco R, Di Pace F, Ponte F. Casteldaccia eye study: prevalence of cataract in the adult and elderly population of a Mediterranean town. Int Ophthalmol. 1994; 18:363-371.
7. Klein BE, Klein R, Linton KL. Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study. Ophthalmology. 1992;99:546-552.
8. Leske MC, Connell AM, Wu SY, et al. Prevalence of lens opacities in the Barbados Eye Study. Arch Ophthalmol. 1997; 115:105-111.
9. Mitchell P, Cumming RG, Attebo K, Panchapakesan J. Prevalence of cataract in Australia: the Blue Mountains eye study. Ophthalmology. 1997;104:581-588.
10. Nirmalan PK, Krishnadas R, Ramakrishnan R, et al. Lens opacities in a rural population of southern India: the Aravind Comprehensive Eye Study. Invest Ophthalmol Vis Sci. 2003; 44:4639-4643.
11. Seah SK, Wong TY, Foster PJ, et al. Prevalence of lens opacity in Chinese residents of Singapore: the tanjong pagar survey. Ophthalmology. 2002;109:2058-2064.
12. West SK, Munoz B, Schein OD, et al. Racial differences in lens opacities: the Salisbury Eye Evaluation (SEE) project. Am J Epidemiol. 1998;148:1033-1039.
13. Krishnaiah S, Vilas K, Shamanna BR, et al. Smoking and its association with cataract: results of the Andhra Pradesh eye disease study from India. Invest Ophthalmol Vis Sci. 2005;46: 58-65.
14. Athanasiov PA, Casson RJ, Sullivan T, et al. Cataract in rural Myanmar: prevalence and risk factors from the Meiktila Eye Study. Br J Ophthalmol. 2008;92:1169-1174.
15. Athanasiov PA, Edussuriya K, Senaratne T, et al. Cataract in central Sri Lanka: prevalence and risk factors from the Kandy Eye Study. Ophthalmic Epidemiol. 2010;17:34-40.
16. Duan XR, Liang YB, Wang NL, et al. Prevalence and associations of cataract in a rural Chinese adult population: the Handan Eye Study [published online ahead of print April 11, 2012]. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/ s00417-012-2012-x.
17. Husain R, Tong L, Fong A, et al. Prevalence of cataract in rural Indonesia. Ophthalmology. 2005;112:1255-1262.
18. Ostberg A, Loth A, Gustafson D, Lindblom B. Skovde cataract study: I. Prevalence of lens opacities in a Swedish community. Ophthalmology. 2006;113:970-975.
19. Tsai SY, Hsu WM, Cheng CY, et al. Epidemiologic study of agerelated cataracts among an elderly Chinese population in Shih-Pai, Taiwan. Ophthalmology. 2003;110:1089-1095.
20. Varma R, Torres M. Prevalence of lens opacities in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111: 1449-1456.
21. Vashist P, Talwar B, Gogoi M, et al. Prevalence of cataract in an older population in India: the India study of age-related eye disease. Ophthalmology. 2011;118:272-278. e1-2.
22. Xu L, Cui T, Zhang S, et al. Prevalence and risk factors of lens opacities in urban and rural Chinese in Beijing. Ophthalmology. 2006;113:747-755.
23. Kanthan GL, Wang JJ, Rochtchina E, et al. Ten-year incidence of age-related cataract and cataract surgery in an older Australian population. The Blue Mountains Eye Study. Ophthalmology. 2008;115:808-814. e1.
24. Klein BE, Klein R, Lee KE. Incidence of age-related cataract over a 10-year interval: the Beaver Dam Eye Study. Ophthalmology. 2002;109:2052-2057.
25. Klein BE, Klein R, Lee KE, Gangnon RE. Incidence of agerelated cataract over a 15-year interval the Beaver Dam Eye Study. Ophthalmology. 2008;115:477-482.
26. Klein BE, Klein RE, Lee KE. Incident cataract after a five-year interval and lifestyle factors: the Beaver Dam eye study. Ophthalmic Epidemiol. 1999;6:247-255.
27. Leske MC, Wu SY, Nemesure B, et al. Nine-year incidence of lens opacities in the Barbados Eye Studies. Ophthalmology. 2004;111:483-490.
28. McCarty DJ, Fu CL, Harper CA, et al. Five-year incidence of diabetic retinopathy in the Melbourne Visual Impairment Project. Clin Experiment Ophthalmol. 2003;31:397-402.
29. Panchapakesan J, Mitchell P, Tumuluri K, et al. Five year incidence of cataract surgery: the Blue Mountains Eye Study. Br J Ophthalmol. 2003;87:168-172.
30. Varma R, Richter GM, Torres M, et al. Four-year incidence and progression of lens opacities: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2010;149:728-734. e1-2.
31. Zhang JS, Xu L, Wang YX, et al. Five-year incidence of agerelated cataract and cataract surgery in the adult population of greater Beijing: the Beijing Eye Study. Ophthalmology. 2011; 118:711-718.
32. Rao GN, Khanna R, Payal A. The global burden of cataract. Curr Opin Ophthalmol. 2011;22:4-9.
33. McCarty CA, Mukesh BN, Dimitrov PN, Taylor HR. Incidence and progression of cataract in the Melbourne Visual Impairment Project. Am J Ophthalmol. 2003;136:10-17.
34. Tan AC, Wang JJ, Lamoureux EL, et al. Cataract prevalence varies substantially with assessment systems: comparison of clinical and photographic grading in a population-based study. Ophthalmic Epidemiol. 2011;18:164-170.
35. Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol. 2004;122:487-494.
36. Hall AB, Thompson JR, Deane JS, Rosenthal ARLOCS III versus the Oxford Clinical Cataract Classification and Grading System for the assessment of nuclear, cortical and posterior subcapsular cataract. Ophthalmic Epidemiol. 1997;4:179-194.
37. Foong AW, Saw SM, Loo JL, et al. Rationale and methodology for a population-based study of eye diseases in Malay people: The Singapore Malay eye study (SiMES). Ophthalmic Epidemiol. 2007;14:25-35.
38. Wong TY, Chong EW, Wong WL, et al. Prevalence and causes of low vision and blindness in an urban malay population: the Singapore Malay Eye Study. Arch Ophthalmol. 2008;126:1091-1099.
39. Chong EW, Lamoureux EL, Jenkins MA, et al. Sociodemographic, lifestyle, and medical risk factors for visual impairment in an urban asian population: the singapore malay eye study. Arch Ophthalmol. 2009;127:1640-1647.
40. Lavanya R, Jeganathan VS, Zheng Y, et al. Methodology of the Singapore Indian Chinese Cohort (SICC) eye study: quantifying ethnic variations in the epidemiology of eye diseases in Asians. Ophthalmic Epidemiol. 2009;16:325-336.
41. Chylack LT, Jr., Wolfe JK, Singer DM, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol. 1993;111:831-836.
42. Klein BE, Klein R, Linton KL, et al. Assessment of cataracts from photographs in the Beaver Dam Eye Study. Ophthalmology. 1990;97:1428-1433.
43. R Development Core Team. R: A Language and Environment for Statistical Computing. 2.14.2 ed. Vienna: R Foundation for Statistical Computing; 2012.
44. Stone M. Cross-validation: A review. Math Operationsforsch Statist, Ser: Statistics 1978;9:127-139.
45. Livingston PM, Guest CS, Stanislavsky Y, et al. A populationbased estimate of cataract prevalence: the Melbourne Visual Impairment Project experience. Dev Ophthalmol. 1994;26: 1-6.
46. Kanthan GL, Mitchell P, Burlutsky G, et al. Pseudoexfoliation syndrome and the long-term incidence of cataract and cataract surgery: The Blue Mountains Eye Study [published online ahead of print October 1, 2012]. Am J Ophthalmol. doi: 10. 1016/j.ajo.2012.07.002.
47. Klein BE, Howard KP, Lee KE, et al. The relationship of cataract and cataract extraction to age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2012;119:1628-1633.
48. Ansari RR, Datiles MB, 3rd. Use of dynamic light scattering and Scheimpflug imaging for the early detection of cataracts. Diabetes Technol Ther. 1999;1:159-168.
49. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
50. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
51. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
52. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond). 2008;22:590-591.
53. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248.